仟源医药 (300254)

SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD

ASZ

Tags

Nicotinamide Mononucleotide (NMN) ConceptIndividual ShareholdingsGeneric DrugsChemical PharmaceuticalsGene ConceptInfant and Child ConceptSmall Cap Non-FinancialMicro Cap Selected StocksMicro Cap StocksVitaminsDispersed ShareholdingBidding TargetsSZSE Medicine Equal Weight IndexCSI Circulation IndexCSI All-share IndexShenzhen A-Share Pharmaceutical IndexChiNext Composite IndexOptimized Fertility (Three-child)Gene SequencingExpected Loss/DeclineQFII HoldingsFund Heavy HoldingsPrivate PlacementHuijin ConceptShareholding Increase CommitmentExpected Profit/IncreasePrecision MedicineSZSE Composite IndexNew IndexEmerging Industries Composite IndexManufacturing IndexCSI A-Share IndexCNI A-Share Index

K-Line Chart

No K-line data available

Company NameShanxi QianYuan Pharmaceutical Group Co., Ltd.
Listing Date2011-08-19
Issue Price13RMB
Registered Capital25610.856310k RMB
Legal RepresentativeZhao Qun
Registered AddressNo. 2 Cuwei Street, Biomedical Technology Innovation Industrial Park, Datong Economic and Technological Development Zone, Shanxi Province
IndustryChemical Pharmaceuticals
Main BusinessResearch and development, production, and sales of pharmaceuticals and health foods, as well as medical and health services and commercial businesses such as medical diagnosis, gene preservation, and pregnancy environment testing.
Company ProfileShanxi QianYuan Pharmaceutical Group Co., Ltd. is a pharmaceutical listed enterprise integrating production, research and development, and sales. The company changed its name to Shanxi QianYuan Pharmaceutical Co., Ltd. in June 2010, and successfully listed on the Shenzhen Stock Exchange's ChiNext board on August 19, 2011. In September 2014, the company was renamed Shanxi QianYuan Pharmaceutical Group Co., Ltd., with the stock abbreviation "QianYuan Pharmaceutical" (Stock Code: 300254).

Stock Details

1. Key Indicators

  • Total Shares(W): 25610.86
  • Circulating A-Shares(W): 22437.79
  • Earnings Per Share(RMB): 0.0922
  • Net Assets Per Share(RMB): 1.1485
  • Operating Revenue(W RMB): 61147.34
  • Total Profit(W RMB): 7736.93
  • Net Profit Attributable to Parent(W RMB): 2232.74
  • Net Profit Growth Rate(%): -49.43
  • Weighted Return on Equity(%): 8.1000
  • Operating Cash Flow Per Share(RMB): 0.2940
  • Undistributed Profit Per Share(RMB): -0.8542
  • Capital Reserve Per Share(RMB): 1.1785

2. Main Business

The main business covers:

  • Research, production, and sales of pharmaceuticals
  • Research, production, and sales of health foods
  • Medical health services such as medical diagnosis and gene preservation
  • Commercial services

3. Company Basic Information

  • Company Name: Shanxi C and Y Pharmaceutical Group Co., Ltd.
  • Listing Date: 2011-08-19
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 1378, Heng'an Street, Economic and Technological Development Zone, Datong City, Shanxi Province
  • Website: www.cy-pharm.com
  • Company Profile: The company was established through the lawful overall change of Qianyuan Co., Ltd. On May 16, 2010, all shareholders of Qianyuan Co., Ltd., as promoters, jointly signed the "Promoter Agreement" for the establishment of the company, unanimously agreeing to convert the audited net assets of RMB 115,464,427.25 as of April 30, 2010, into 100 million shares at a conversion ratio of 1.1546442725:1, with the balance of RMB 15.4644 million credited to capital reserve. On May 31, 2010, Lixin Certified Public Accountants Co., Ltd. issued the "Capital Verification Report" (Xin Hui Shi Bao Zi (2010) No. 24365). On June 6, 2010, after approval and registration by the Datong City Administration for Industry and Commerce in Shanxi Province, the company obtained the "Business License of Enterprise Legal Person" with registration number 140200400002021.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shandong Sanzu Private Securities Investment Fund Management Co., Ltd. - Sanzu Sky No.1 Private Securities Investment Fund Private Securities Investment Fund 311.49 1.38
2 Shandong Sanzu Private Securities Investment Fund Management Co., Ltd. - Sanzu Sky No.5 Private Securities Investment Fund Private Securities Investment Fund 264.04 1.17
3 MORGAN STANLEY &CO.INTERNATIONAL PLC. QFII 151.85 0.67
4 ChinaAMC Dingrong Bond Securities Investment Fund Class A Fund 3.39 0.02
5 ChinaAMC Ruipan Taimao Hybrid Securities Investment Fund Class A Fund 2.23 0.01
6 Western Lead Quantitative Select One-Year Holding Hybrid Securities Investment Fund Class A Fund 2.22 0.01
7 ChinaAMC PanTai Hybrid Securities Investment Fund (LOF) Class A Fund 1.97 0.01
8 ChinaAMC Ruipan Taixing Hybrid Securities Investment Fund Class A Fund 0.57 0.00
9 Everbright Baodexin Quantitative Core Securities Investment Fund Class A Fund 0.47 0.00
10 ChinaAMC Wenjin Zengyi One-Year Holding Hybrid Securities Investment Fund Class A Fund 0.44 0.00

5. Concept Sectors

  • Infant and Child Concept
  • Elderly Care Concept
  • Gene Concept
  • Vitamins
  • Generic Drugs
  • NMN Concept
  • Hepatitis Concept
  • Innovative Drugs
  • Micro-Cap Stocks
  • Being Acquired
  • Dispersed Shareholding
  • Individual Shareholding
  • Small-Cap Non-Marginable
  • Micro-Cap Selection

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information